Pembrolizumab NCT07695311 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Not yet recruiting

Recruitment status

24

Planned enrollment

2029-10-01

Primary-completion proxy

Executive view

NCT07695311 evaluates Pembrolizumab in Ewing Sarcoma. The disclosed sponsor is The Case Comprehensive Cancer Center, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Safety of EWSR1 immunotherapy, measured by number of participants with grade 4 immunotherapy-related adverse events, assessed over Up to 6 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07695311 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Ewing Sarcoma landscape. Drug & Asset MCP drug_fetch was queried for Pembrolizumab, while Company & Deal Intelligence MCP organization_fetch was queried for The Case Comprehensive Cancer Center.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07695311	Pembrolizumab	Phase 1 / Not yet recruiting	The Case Comprehensive Cancer Center	United States	Safety of EWSR1 immunotherapy, measured by number of participants with grade 4 immunotherapy-related adverse events Up to 6 months	2029-10-01
NCT07658768	Indocyanine Green	Early Phase 1 / Not yet recruiting	Abramson Cancer Center	Geography not reported	Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) 1 year	2027-05-01
NCT07648069	Sintilimab	Phase 1 / Recruiting	Sun Yat-Sen University	China	Incidence and severity of adverse events 120 days	2026-12-31
NCT07633756	Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )	Phase 1 / Recruiting	M.D. Anderson International España SA	United States	Safety and adverse events (AEs). Through study completion; an average of 1 year	2029-12-26
NCT07553260	Sodium Chloride	Not Applicable / Not yet recruiting	King Hussein Cancer Center	Jordan	Incidence of Grade II or Higher Acute Radiation Dermatitis During radiotherapy treatment period (approximately 6-7 weeks)	2027-05-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07695311 is a Phase 1, not yet recruiting study with 24 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Safety of EWSR1 immunotherapy, measured by number of participants with grade 4 immunotherapy-related adverse events” over “Up to 6 months.” The retrieved endpoint description is: Safety will be achieved in the EWSR1 immunotherapy monotherapy cohort if no participant has grade 4 EWSR1 immunotherapy-related toxicity.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 24 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Ewing Sarcoma. These records do not establish direct evidence for NCT07695311 unless the registration number matches.

A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Ace…

Phase 3; n=1016; ARR(Mean) = 0.182 Relapses per participant per year (Standard Error, 0.022); ARR(Mean) = 0.260 Relapses per participant per year (Standard Error, 0.029) Source: https://clinicaltrials.gov/ct2/show/results/NCT04121221

Real-world efficacy of fixed-dose weekly paclitaxel for AIDS-associated Kaposi Sarcoma: a 16-year cohort study in Rio de Janeiro, Brazil

Not Applicable; n=176; CR = 58.0 % Source: https://programme.aids2026.org/Abstract/Abstract/?abstractid=10933

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Angiosarcoma

Phase 2; n=6; Progression-free Rate at 9 Cycles = 67 Percentage of participants (95% Confidence Interval, 20 - 90) Source: https://clinicaltrials.gov/ct2/show/results/NCT05026736

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Pembrolizumab is indexed as Monoclonal antibody with PD-1 biology and a global stage of Approved. The asset profile lists Merck & Co., Inc. as an originator or developer.

The Case Comprehensive Cancer Center is indexed in United States with the website http://www.case.edu/cancer. Case Comprehensive Cancer Center is an NCI-designated cancer center. The record lists 7 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Pembrolizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07695311
Protocol source: https://clinicaltrials.gov/study/NCT07695311
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

Pembrolizumab in Ewing Sarcoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Safety of EWSR1 immunotherapy, measured by number of participants with grade 4 immunotherapy-related adverse events and 2029-10-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP